TuanHoangVuMD

Neurology • Tampa, FL

Neuromuscular Medicine, Neurophysiology

Professor of Neurology, University S Fla College of Medicine

Join to view full profile

Dr. Vu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vu's full profile

Already have an account?

Office
13220 USF Laurel Dr, Tampa, FL 33612
Tampa, FL 33612
Phone+1 813-974-9413

Fax+1 813-974-7138

Education & Training

New York-Presbyterian HospitalPost-Doctoral Fellowship, 1994 - 1996
New York Presbyterian Hospital (Columbia Campus)Fellowship, Neuromuscular Medicine (Neurology), 1993 - 1994
New York Presbyterian Hospital (Columbia Campus)Residency, Neurology, 1990 - 1993
Penn State Milton S Hershey Medical CenterInternship, Internal Medicine, 1989 - 1990
Pennsylvania State University College of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2010 - 2026
PA State Medical License 1989 - 2010
NJ State Medical License 1994 - 2003
NY State Medical License 1992 - 2002
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine
American Board of Electrodiagnostic MedicineFellow

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

Phase 3 Study of Dexpramipexole in ALS Start of enrollment: 2011 Mar 01
Completed
Phase 3
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis Start of enrollment: 2011 Jan 01
Completed
Not Applicable
Subcutaneous Immunoglobulin for CIDP Start of enrollment: 2014 Sep 01
Completed
Not Applicable
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Start of enrollment: 2017 May 15
Completed
Phase 2
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Start of enrollment: 2017 Oct 11
Completed
Phase 2
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Start of enrollment: 2019 Jun 03
Completed
Phase 3
Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Start of enrollment: 2021 Jun 28
Active, not recruiting
Phase 2
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL) Start of enrollment: 2021 Dec 22
Active, not recruiting
Phase 2
A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis Start of enrollment: 2021 Dec 14
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gra...
Ali A Habib, Michael Benatar, Tuan Vu, Andreas Meisel, Shahram Attarian
European Journal of Neurology. 2024-12-01
1 citations
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label ex...
James F Howard Jr, Tuan Vu, George Li, Denis Korobko, Marek Smilowski
Neurotherapeutics. 2024-09-01
2 citations
Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
James F Howard Jr, Tuan Vu, Renato Mantegazza, Hani Kushlaf, Shigeaki Suzuki
Muscle & Nerve. 2024-05-01

Journal Articles

Terminal Complement Inhibitory Ravulizumab in Generalized Myasthenia Gravis.
Tuan Vu, M.D.,1 Andreas Meisel, M.D.,2 Renato Mantegazza, M.D.,3 Djillali Annane, M.D.,4 Masahisa Katsuno, M.D.,5 Rasha Aguzzi, M.S.,6 Ahmed Enayetallah, M.D., Ph.D.,6..., NEJM Evidence 1 (5). April 2022., 4/2022

Press Mentions

Cartesian Therapeutics Expands Clinical Advisory Board with Five Internationally Recognized Experts in AutoimmunityMarch 28th, 2023

Grant Support

Mitochondrial DNA Depletion In Hepatoneural SyndromesNational Institute Of Neurological Disorders And Stroke2001
Mitochondrial DNA Depletion In Human DiseaseNational Institute Of Neurological Disorders And Stroke1996–2000

Other Languages

Vietnamese